The Board of Directors is comprised of five members who bring a wealth of diverse leadership and clinical research experience to their roles:
- John Doll – Chief Operating Officer of RWJBarnabas Health
- Mark Kolb – Entrepreneur in Residence at Tech Council Ventures
- Steven Libutti, MD, FACS – Director of Rutgers Cancer Institute of New Jersey and Vice Chancellor for Cancer Programs, Rutgers Biomedical and Health Sciences
- Reynold Panettieri, Jr., MD – Director of the Institute for Translational Medicine and Science and Vice Chancellor for Translational Medicine and Science at Rutgers University
- David Moore, Chairman of the Board and CEO of Vitalief
David Moore, Vitalief Chairman and CEO, observed, “Our Board of Directors represents the best of the healthcare, clinical research, and technology industries. They also reflect the research organizations and clinical trial teams that we serve. Their experience and knowledge are invaluable assets to Vitalief as we continue to grow, and we appreciate their guidance and support of our goals.”
John Doll, Chief Operating Officer of RWJBarnabas Health, commented, “It’s a pleasure to be working with such an accomplished Board who are so closely aligned in their commitment to the organization and its strategic goals.”
“The value proposition that Vitalief offers is particularly relevant at this time in history,” noted Mark Kolb, Entrepreneur in Residence at Tech Council Ventures. “Changing workforce dynamics are demanding a new approach, and Vitalief is stepping up to address this unmet need in the marketplace. I am excited to be contributing as a board member.”
Steven Libutti, MD, FACS, Director of Rutgers Cancer Institute of New Jersey and Vice Chancellor for Cancer Programs, Rutgers Biomedical and Health Sciences, commented, “Vitalief’s mission and vision resonate with me. I have experienced first-hand the struggles of recruiting, training, and retaining research teams. I really appreciate Vitalief’s thoughtful approach to these continuing challenges.”
Reynold Panettieri, Jr., MD, Director of the Institute for Translational Medicine and Science and Vice Chancellor for Translational Medicine and Science at Rutgers University, added, “Clinical trials are becoming increasingly complex, and experienced clinical research professionals are difficult to find. Vitalief’s commitment to recruiting and retaining top talent is a game-changer. I am happy to be part of such an exciting effort.”
